Related Experiment Video
Updated: Jun 28, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Review of tissue plasminogen activator, ischemic stroke, and potential legal issues
Bryan A Liang1, Robert Lew, Justin A Zivin
1Institute of Health Law Studies, California Western School of Law, San Diego, CA 92101, USA. baliang@alum.mit.edu
Abstract:
The use of tissue plasminogen activator in ischemic stroke is controversial. Many practicing physicians believe that its usefulness is established, while others, including professional specialty societies, are less sanguine. A review of the literature appears to show that the use of tissue plasminogen activator is efficacious and can result in highly improved outcomes for a majority of eligible patients. These findings may implicate important potential legal issues. Informed consent concerns and, potentially, medical malpractice claims may result, particularly in the context of evidence-based practice, pay for performance, and the currently limited use of tissue plasminogen activator for eligible patients.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Venous Thrombosis III: Interprofessional Care
Hemorrhagic Stroke ll: Pathophysiology
Stroke: Introduction and Types
Transient Ischemic Attack l: Introduction

